Who we are

Hypertension Canada is the country’s only national non-profit organization dedicated solely to the prevention and control of hypertension and its complications. Powered by a professional volunteer network of the nation’s leading multidisciplinary experts, Hypertension Canada pursues its mission through research, professional and public education, and advocacy for healthy environments. Learn more at www.hypertension.ca.

What drives us

At Hypertension Canada, our mission and vision are at the core of everything we do. We foster the health care professional’s network for excellence in hypertension research, education and care.

Mission: Advancing health through the prevention and control of high blood pressure and its complications.

Vision: Canadians will have the healthiest and best managed blood pressure in the world.

How we’ll get there

- Inspire innovation
  Hypertension Canada is proud to invest in promising and talented hypertension investigators. We support the important work of current and future investigators through strategic partnerships; we foster career mentoring and succession planning; and collaboratively work with clinicians and patients to set hypertension research priorities.

- Invest in education
  Hypertension Canada creates and publishes the world-renown clinical practice guidelines for hypertension diagnosis, treatment, and control, and supports health care professionals in their application. The Hypertension Canada Guidelines are developed by a multidisciplinary task force and are rigorously reviewed and annually updated. We provide a suite of accredited educational programs for health care professionals based on the guidelines, and create educational resources for professionals to use with their patients.

- Initiate conversations
  Hypertension Canada works with stakeholders, partners, and government to improve awareness, prevention, and treatment of hypertension and its complications. We make it our business to keep abreast of issues affecting people with hypertension and the professionals who treat them, and seek opportunities to make positive changes that bring us closer to achieving our mission.

- Intentionally engage
  Our work is most effective when we collaborate. Hypertension Canada proudly leads the conversation on emerging hypertension issues, and engages our community in innovative new ways. We foster the health care professional’s network for excellence in hypertension research, education and care.

<table>
<thead>
<tr>
<th>Topic</th>
<th>September 19 - 21, 2016</th>
<th>Montréal, Quebec</th>
<th>Sheraton Montreal Airport Hotel</th>
<th>#CHC17</th>
<th>Hypertension and Beyond</th>
<th>October 19-21, 2016</th>
<th>Hypertension Canada</th>
<th>Join us</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Remarks</td>
<td>18:00 - 18:10</td>
<td>Room: Petit Salon</td>
<td>Dr. Ross Feldman, Canadian Hypertension Congress Chair</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening Panel Discussion</td>
<td>18:10 - 19:00</td>
<td>Topic: Especially in Cases of Intensive Intervention, How Might National Pharmacare Affect Patient and Provider Access to Antihypertensive Medications in Canada?</td>
<td>Moderator: Dr. Milan Gupta</td>
<td>Panelists: Dr. Tavis Campbell, Dr. Glenn Doucet, Dr. Sarah Beech, Mr. Denis Morrice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Closing Remarks</td>
<td>19:00 - 20:30</td>
<td>Poster Session # 1</td>
<td>Room: Grands Salons</td>
<td>Biomedical Research Track</td>
<td>Clinical Research Track</td>
<td>2016 Canadian Hypertension Congress</td>
<td><a href="http://www.hypertension.ca">www.hypertension.ca</a></td>
<td>@HTNCanada</td>
</tr>
</tbody>
</table>

Wednesday, October 19, 2016

Opening Remarks
Room: Petit Salon
Dr. Ross Feldman, Canadian Hypertension Congress Chair

Opening Panel Discussion
Topic: Especially in Cases of Intensive Intervention, How Might National Pharmacare Affect Patient and Provider Access to Antihypertensive Medications in Canada?
Moderator: Dr. Milan Gupta
Panelists: Dr. Tavis Campbell, Mr. Glenn Doucet, Ms. Sarah Beech, Mr. Denis Morrice

Closing Remarks
Dr. Ernesto Schifino, President and Chair of the Board, Hypertension Canada

Poster Session # 1
Room: Grand Salon

Biomedical Research Track

BMR1 Resveratrol Alleviates Hyper Proliferation of Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats: Role of ROS and ROS-Mediated Signaling - Sara Almajdoob
BMR2 Angiotensin-II-Induced Expression of the Early Growth Response Protein-1 is attenuated by c-AMP Agonists in Vascular Smooth Muscle Cells - Estelle Rollande Simo Chayour
BMR3 The Effect of Bradykinin and Bradykinin B2 Receptors on High-Glucose-Induced Senescence of C3H-101 Positive CPGs - Yineng Sun
BMR4 Canagliflozin, a Sodium-Gluco- Co-Transporter 2 (SGLT-2) Blocker, Normalizes Blood Glucose without Affecting Systemic Blood Pressure and Infrarenal Renin-Angiotensin System Gene Expression and Kidney Injury in Akita Mice with Type 1 Diabetes - Chito-Han Wu
BMR5 Induction of Human Endothelin-1 Overexpression for 3 months Causes Blood Pressure Rise and Small Artery Endothelial Dysfunction and Stiffening - Suzen Coelho
BMR6 Slatin Therapy Modulates the Adiponectin Receptor Pathway in Circulating Monocytes in Subjects with Severe Atherosclerosis and in Hypertensive Subjects High-risk for Cardiovascular Disease - Kania Gasbarrino
BMR7 Evaluation of the Cardiovascular and Kidney Functions of the Male Rat: Rats submitted to a Model of Arterial Hypertension after Treatment with the Aqueous Extract of Baccharis trimera - Rodrigo Liberato Goncalves Viana
BMR8 Alamandine and Angiotensin-(1-7) Prevent Programming of Cardiac Dysfunction Induced by Neonatal Exposure to High Oxygen in Rats - Thu-An Ma Vo
BMR9 Regional Heterogeneity in the Stoichiometry of Vascular Phosphate and Calcium Accrual: Differential Dependency on Vitamin K Status - Jason Zelt
BMR10 SREBP2 Expression is regulated by GPER Differentially in HepG2 Cells vs. Human Hepatocytes - Qiang Dong
BMR11 Matrix Metalloproteinase 2 Knockout Projects from Angiotensin II-induced Vascular Injury - Julio Cesar Fouladb Aquino

Clinical Research Track

CR1 The Aortic Health Impact of Intradialytic Pedaling Exercise in a Hemodialysis Population - Alexandre Cooke
CR2 Predicting Cognitive Decline in Older Adults: Aortic Stiffness and Framingham Cardiovascular Risk Score - Xavier Trudel
CR3 Dietary Sodium and Potassium Intake in a Referred Population with Difficult to Control Hypertension - Swapan Mehta
CR4 The Relationship between Hypertensive Disorders of Pregnancy and Incident Hypertension: A Couple Analysis - Anthe-Sophie Braeux
CR5 Angioteinsin-like-1 is Positively Correlated with Aortic Stiffness and Mortality after Kidney Transplantation - Mano-Flor Dejardin
CR6 Self Measurement of Blood Pressure Using an Office Automated Device - Monica Bicca
CR7 Effects of Fixed Versus Auto-Titrating Continuous Positive Airway Pressure on Vascular Function in Patients with Resistant Hypertension and Obstructive Sleep Apnea - Karen Tran
CR8 Environmental Factors and Hypertension: The Role of Particulate Matter (PM) - Omar Albassem
CR9 Aortic Reserve Function and Aortic-to-Basilar Stiffness Gradient in a Dialysis Population - Catherine Forfar
CR10 Exercise and Antioxidant Intake in Aging Normotensive and Hypertensive Individuals - Stéphanie Mercier
CR11 Optimal Blood Pressure Readings Aim to Renal Protection in Chronic Kidney Diseases in the Geriatric Population - Samia Li Risotto
Thursday, October 20, 2016

Biomedical Research Track
Room: Petit Salon
Each 15 min session includes a 5 min Q&A
Each 30 min session includes a 10 min Q&A

Clinical/Outcomes/Population Research Track
Room: Grand Salon
Each 15 min session includes a 5 min Q&A
Each 30 min session includes a 10 min Q&A

---

Hypertension Canada’s Annual General Meeting with Continental Breakfast

Biomedical # 1
Co-chairs: Dr. Dylan Burger & Pierre Potard

09:00 - 10:30

10:30 - 11:00
Break in Mezzanine

11:00 - 12:30

Biomedical # 2
Co-chairs: Dr. Michael D’Alimonte & John Louie

09:00-12:30 as a Potential Master Regulator in Angiogenesis II-Induced Vascular Hypertrophy

11:55 Effective Glucose Exposure on Endothelial Micro Particle Formation and Coagulation Activation – Madhav Turner

12:00-12:30 STATE OF THE ART – The Immune System & Cardiovascular Disease – David Celemis

12:30-14:00

Lunch in the Souloange-Mercier-Lawrence-Dorrall

14:00 - 15:30

11:00 Senior Investigator Award Lecture – Molecular Studies of Vascular Smooth Muscle: Looking Back and Jumpping Forward – Dr. Monoran Loftus

11:30 Vancouver 2010 Lecture Home – Home SP Monitoring: Primary Role in Hypertension Management – Dr. George Gengou

12:00-12:30 Hypertension Canada’s Recognition Awards – Dr. Nicole Khan

13:30 - 17:30

Poster Session # 2A

---

Biomedical Research Track

BMR1 Transtentorial High Oxygen Exposure Accelerates Adult Cardiac Baseline and Ang-II induced Focaladie and Postinfarctional Recovery Reaction – Ahmad Moham

BMR2 Evaluation of Differential Effects for the Assessment of Arterial Stiffness – Corinna Seekan

BMR3 Neutrophilic Peptide Receptor C-agonist Affects the Enhanced Expression of Sup/PC17 Proteins and Vascular Smooth Muscle Cell Hypertrophy: In Spontaneously Hypertensive Nephrectomized Rats: Role of ROS and ROS-Mediated Signaling – Amin Jani

BMR4 Renovascular Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Hypertrophy: Molecular Mechanisms – Shahrour Hassam

BMR5 Chronic Information and Sympathetic Nerve Mediated Contraction in Rat Isolated Carotid Artery – Jociet Fai Suh

BMR6 Daily Growth Response Protein TGF-β1 Depression by Hydrogen Peroxide is mediated via Protein Kinase C-Dependent Activation of MAPK and Protein Kinase B Signaling in Vascular Smooth Muscle Cells – Vincent Reneau

BMR7 ANG-II and/or Deseretinization: A Mouse Model of RENAL and Depression-induced Kidney Injury – Jean-Francois Thibodeau

BMR8 Concentration-Dependent Effects of Metformin on the Vascular Endothelium – Chi Yuggle

BMR9 Beta Endoart – Jeffrey Alford

BMR10 Mapping of Chromosome 2 Regions linked to Vascular Inflammation using Congenic Rats – Sofiene Ourad

BMR11 Self Sensitive Hypertension in Chronic Kidney Disease – Savera Nabeen

BMR12 Effect of Phase 0 Erythrocyte Inducer, Sulforaphane on Hypertension and Renal Arterial Structure – All Reggia

Clinical Outcomes/Population Research Track

CR1 A Trend Analysis of Hypertension Disease Severity in Sri Lanka during 2000-2015 – Priyadarshini Amarasena

CR2 Attitudes of Obstetrician Medical Specialists about Out-of-Office Blood Pressure Measurement in Cases of the Diagnosis for White Coat Hypertension – Kaimin Tan

CR3 Hospital Hypertension and Effortful Blood Pressure Amongst 2364 White-Collar Workers – Philippe Bouchu

CR4 Improvement in Blood Pressure Following Group-Based Diabetes Prevention Programs in Families with Recent Gestational Diabetes – Anne Sophie Brasseau

CR5 Dietary Calcium Intake: Does it affect Vascular Health? – Shrikrishna Das

CR6 Regional Vascular Stiffness in Response to Nitroglycerin and Their Impact on Arterial Stiffness Gradient – Catherine Kotter

CR7 The Effect of Alcohol Consumption on Blood Pressure: A Systematic Review and Meta-Analysis of Intervention Studies – Michael Robins

CR8 The Relationship of Vitamin D and Parathormone Levels with Hypertension: A 9 Different in White Coat and Sustained Hypertension - Frank Aigiz

CR9 The Alberta Vascular Risk Reduction Community Pharmacy Project in Patients with CKD (RedACh CKD) – Yassir A Almahmo

CR10 Non-Invasive and Continuous Blood Pressure Prediction from Pulse Transit Time Using ECG and PPG Signals – Dr. Mohamed Othman

CR11 Screening for Hypertension During Consultation Can Be a Potent Tool for a Pilot Study – Andre Michaud

CR12 Coronary Blood Flow is Reduced in Patients with Hypertension which should Increase the Risk of Myocardial Ischemia with Development of Coronary Artery Disease – Simon Robin

---

Friday, October 21, 2016

Biomedical Research Track
Room: Petit Salon
Each 15 min session includes a 5 min Q&A
Each 30 min session includes a 10 min Q&A

Clinical/Outcomes/Population Research Track
Room: Salon La Tour
Each 15 min session includes a 5 min Q&A
Each 30 min session includes a 10 min Q&A

Primary Care Track
Room: Grand Salon
Each 20 min session includes a 5 min Q&A

---

Breakfast Symposium in the Souloange-Mercier-Lawrence-Dorrall

Moderator: Dr. Ross Feldman
Panelists: Dr. George Gengou, Dr. Phil McMahon & Dr. Sheldon Tobe

08:00 - 09:30

Biomedical # 3

Co-chairs: Dr. Simon Robson & Ross Touhy

08:00 - 08:30 STATE OF THE ART – The Role of Oligo-Urgent Cardiac Care in Diabetic Stroke – Dr. Melanie Johns

08:30 - 10:00 STATE OF THE ART – The Role of Oligo-Urgent Cardiac Care in Diabetic Stroke – Dr. Melanie Johns

10:00 - 10:45 Cardiometabolic Adaptations to Systemic Energy State – Safaa Naiel

10:45 - 11:00 Hypertension and Cardiometabolic Physiology – Victor Tat

---

Primary Care # 2

Special Populations
Co-chairs: Drs. George Gennaro & Richard Parfitt

08:00 - 10:00 Hypertension in Children: A Practical Approach – Dr. Kevin Innes

10:00 - 12:00 Reducing the Risk of Heart Disease in Women Under Treatment or Overdose – Dr. Krista Fedor

12:00 - 12:30 Applying Hypertension Guidelines in the Older Elderly – Dr. Ross Feldman

---

Lunch Symposium in the Souloange-Mercier-Lawrence-Dorrall

Topic: So you Think you’re a Hypertension Expert?

Host: Dr. Phil McMahon
Panelists: Dr. Gerald Moore, Dr. Steika Daskalopoulo, Dr. Ernesto Schniffl, Dr. Sheldon Tobe & Dr. Luc Trudel

13:00 - 14:30

Vascular Network Symposium
Chair: Dr. Maurice Naught

13:00 Welcome & Introduction – Dr. Maurice Naught

13:05 Collagen Signaling in Vascular Stiffening and Calcification – Dr. Michelle Bindek

13:15 Large Animal Models of Cardiopulmonary Disease – Dr. Kevin Williams

13:30 Cardiometabolic Adaptations to Systemic Energy State – Dr. Bradford Hill

13:45 - 15:00 House Call in Hypertensive Patient with Diabetes – Freda Cottrell

15:00 - 16:00 Beyond Hypertension: Global Risk Reduction – Dr. Karen Vail

16:00 - 17:00 Vascular Protection: Lifestyle and Cardiometabolic Diseases: An Update – Dr. Brian Donaus

17:00 - 18:00 How to Use the Male Pill on High Risk Patients – Dr. Kevan Spence

---

Primary Care Session # 3

Beyond Hypertension: Global Risk Reduction
Co-chairs: Drs. Simon Rabkin & Ross Tsuyuki

09:30 - 11:00 Preventing and Reversing Cardiovascular Disease – Dr. Michael S Waves

11:00 - 12:00 Reducing the Risk of Hypertension: Beyond Blood Pressure – Dr. Milan Gupta

---

Primary Care Session # 4

Managing the Other Risk Factors and Hypertension
Co-chairs: Dr. Ally Prentice and Alber Gupta

12:30 - 14:00 Management of the Other Risk Factors and Hypertension – Dr. Ally Prentice

14:00 - 15:00 What’s the Scoop? What’s the Drug for ...I Buy? Hypertension Thrombosis Prevention – Dr. Andrew Bateman

15:00 - 16:00 Glycaemic Guidelines: The End of Targets? Beyond Stopped – Dr. Ross Parfitt

---

Acknowledgement

The Continuing Professional Development (CPD) Office of the Faculty of Medicine of the University of Montreal is fully accredited by the Association of Faculties of Medicine of Canada (AFMC) and the Quebec College of Physicians. This activity, by the Continuing Professional Development (CPD) Office of the Faculty of Medicine of the University of Montreal, is an Accredited Group learning Activity under Section 1, as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada for a maximum of 12.25 hours.

This program meets the accreditation criteria of the College of Family Physicians of Canada and has been accredited by the University of Montreal for 12.25 Mainpro+ credits.

For our full scientific program, abstracts, award winners and speaker biographies, visit hypertension.ca/chc.